Table 2.
Studies included in this SLR that examined the role of concomitant glucocorticoids on the risk of HZ development in JAKi-treated patients
| Author, year (ref), country | Study type follow-up | Disease JAKi | Age, yearsa | Key findings | RoB | ||
|---|---|---|---|---|---|---|---|
| Curtis 2019 [41] US | Cohort NR | RA TOFA | 60.3 (12.6) | IR (95% CI)* | HR (95% CI) | Low | |
| TOFA monotherapy | 3.7 (2.9–4.6) | 1.0 (ref) | |||||
| TOFA + MTX | 3.4 (2.3–5.0) | 0.99 (0.64–1.54) | |||||
| TOFA + GCs | 6.0 (4.9–7.5) | 1.75 (1.28–2.41) | |||||
| TOFA + MTX + GCs | 6.5 (4.8–8.8) | 1.96 (1.33–2.88) | |||||
| Guidelli 2021 [67] Italy | Prospective cohort ≤ 48 weeks | RA BARI | 59.0 (11.9) | In BARI-treated patients on GCs, the rate of VZV reactivation was significantly higher compared to other infections (83% vs. 25%; p = 0.034) | Intermediate | ||
| Redeker 2022 [101] Germany | Prospective cohort ≤ 480 weeks | RA TOFA, BARI or UPA | 57.9 (12.5) |
Among JAKi-treated patients, the ER of HZ was comparable between those with and those without concomitant GC use Dose-dependent relationship; HR (95% CI): GCs 5–10 vs. 0 mg/day: 1.24 (0.98 to 1.57) GCs > 10 vs. 0 mg/day: 3.45 (2.14 to 5.55) |
Intermediate | ||
aMean/median (SD/IQR)
*Per 100 patient-years
ref reference, NR not reported, ER event rate, IR incidence rate, HR hazard ratio, CI confidence interval, JAKi Janus kinases inhibitor, TOFA tofacitinib, BARI baricitinib, UPA upadacitinib, RoB risk of bias, VZV varicella zoster virus, GCs glucocorticoids